Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong
Sponsor: The University of Hong Kong
Summary
This study allows to evaluate the strength and duration of immune responses between annual receipt of standard inactivated vaccine and alternative potent vaccines, including annual receipt of adjuvanted inactivated vaccine, annual receipt of high-dose inactivated vaccine, annual receipt of recombinant HA vaccine, and the alternate combinations of the former three vaccines over four years, for identifying improved vaccination strategies for influenza vaccination in older adults in a location experiencing a subtropical pattern in influenza activity.
Official title: Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial
Key Details
Gender
All
Age Range
65 Years - 82 Years
Study Type
INTERVENTIONAL
Enrollment
1861
Start Date
2017-10-07
Completion Date
2026-12
Last Updated
2023-12-11
Healthy Volunteers
Yes
Conditions
Interventions
Standard inactivated influenza vaccine (NH formulation)
0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
High-dose inactivated influenza vaccine (NH formulation)
0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
Locations (1)
The University of Hong Kong
Hong Kong, China